Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Thomas Patrick Kelly sold 5,000 shares of the stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $25.18, for a total value of $125,900.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of DCPH stock opened at $25.89 on Friday. The company has a quick ratio of 18.46, a current ratio of 18.46 and a debt-to-equity ratio of 0.06. Deciphera Pharmaceuticals Inc has a 12 month low of $18.55 and a 12 month high of $45.61. The company has a market capitalization of $956.97 million, a price-to-earnings ratio of -8.66 and a beta of 3.38.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.65) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.65). On average, equities research analysts forecast that Deciphera Pharmaceuticals Inc will post -2.62 EPS for the current year.
Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc lifted its position in shares of Deciphera Pharmaceuticals by 55.4% in the 3rd quarter. Legal & General Group Plc now owns 1,647 shares of the company’s stock worth $64,000 after acquiring an additional 587 shares during the period. Bank of America Corp DE lifted its position in shares of Deciphera Pharmaceuticals by 316.1% in the 2nd quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock worth $103,000 after acquiring an additional 1,982 shares during the period. MetLife Investment Advisors LLC bought a new stake in shares of Deciphera Pharmaceuticals in the 3rd quarter worth approximately $235,000. Rhumbline Advisers bought a new position in shares of Deciphera Pharmaceuticals during the 2nd quarter worth approximately $301,000. Finally, Highland Capital Management LP bought a new position in shares of Deciphera Pharmaceuticals during the 2nd quarter worth approximately $394,000. Institutional investors own 55.04% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Featured Article: Catch-Up Contributions
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.